Background: Non-steroidal anti-inflammatory drugs can reduce the risk of colorectal cancer.
Reportedly, mRNA expression of cyclooxygenase-2 (COX-2) is elevated in human colorectal …

AIM: Recent clinical epidemiological studies have demonstrated the preventive effect of non-
steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer. The underlying …

Chemoprevention of colorectal cancer is a promising science that has particular importance
due to the limited success of current treatments for most advanced common malignancies …

Abstract Cyclooxygenase (COX)‐2 is a possible molecular target for suppression of colon
carcinogenesis by non‐steroidal anti‐inflammatory drugs (NSAIDs). However, the …

Abstract Background and Objectives Epidemiological studies have suggested that the
regular use of nonsteroidal antiinflammatory drugs, which inhibit cyclooxygenase (COX) …

Background Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of
prostaglandins. It exists in two isoforms: COX-1 which is constitutively expressed and COX-2 …

Cyclooxygenase 2 (COX-2) overexpression has been described in sporadic colonic
neoplasia, but its role in ulcerative colitis (UC) neoplastic progression remains unexplored …

The role of cyclooxygenase-2 (COX-2) in tumor neovascularization of human colorectal
carcinoma is yet to be delineated. One hundred colorectal carcinoma specimens were …

Cyclooxygenase-2 (Cox2) is an inductible isoenzyme of cyclooxygenase undetectable in
normal colonic mucosa and overexpressed in 80% colonic tumor. Several works in vitro and …

Recent epidemiologic studies have shown a 40–50% reduction in mortality from colorectal
cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis …